<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01407874</url>
  </required_header>
  <id_info>
    <org_study_id>BCX4208-204</org_study_id>
    <nct_id>NCT01407874</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency</brief_title>
  <official_title>A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioCryst Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioCryst Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the overall safety and tolerability of ulodesine when combined with allopurinol&#xD;
      in subjects with moderate renal insufficiency.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the overall safety and tolerability of ulodesine when combined with allopurinol in subjects with moderate renal insufficiency by assessment of percent change from baseline in CD4+ lymphocytes at Day 85.</measure>
    <time_frame>85 days</time_frame>
    <description>Level of CD4+ lymphocytes to be measured at Day 85 compared to baseline.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Gout</condition>
  <condition>Hyperuricemia</condition>
  <condition>Arthritis</condition>
  <condition>Joint Disease</condition>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo + Allopurinol 200mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ulodesine (BCX4208) 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BCX4208 5mg + Allopurinol 200 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ulodesine (BCX4208) 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BCX4208 10mg + Allopurinol 200mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral dose administered daily for 84 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ulodesine (BCX4208) 5 mg</intervention_name>
    <description>Oral dose administered daily for 84 days.</description>
    <arm_group_label>Ulodesine (BCX4208) 5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ulodesine (BCX4208) 10 mg</intervention_name>
    <description>Oral dose administered daily for 84 days.</description>
    <arm_group_label>Ulodesine (BCX4208) 10mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 to &lt; 70 years&#xD;
&#xD;
          2. Have read and signed the Informed Consent Form&#xD;
&#xD;
          3. Documented diagnosis of gout&#xD;
&#xD;
          4. Documented moderate renal insufficiency&#xD;
&#xD;
          5. Calculated creatinine clearance of ≥ 30 and &lt; 60 mL/min&#xD;
&#xD;
          6. Willing and able to take allopurinol 200 mg every day for the duration of the&#xD;
             Treatment&#xD;
&#xD;
          7. Female participants must be sexually abstinent for 4 weeks prior to Day 1 and continue&#xD;
             abstinence for 4 weeks after completion of study drug, surgically sterile,&#xD;
             postmenopausal,use oral contraceptives for three months prior to study drug dosing&#xD;
             through 4 weeks after completion of study drug, an intrauterine device for 8 weeks&#xD;
             prior to study drug dosing through 4 weeks after completion of study drug,double&#xD;
             barrier contraception method for 4 weeks prior to study drug dosing through 4 weeks&#xD;
             after completion of study drug administration&#xD;
&#xD;
          8. Male participants must be sexually abstinent for 4 weeks prior to Day 1 and continue&#xD;
             abstinence through 90 days after completion of study drug, be &gt; 1 year postvasectomy,&#xD;
             agree to use a condom with spermicide from the start of study drug dosing through 90&#xD;
             days after completion of study drug.&#xD;
&#xD;
          9. Willing and able to provide authorization for the use and disclosure of personal&#xD;
             health information in accordance with Health Insurance Portability and Accountability&#xD;
             Act (HIPAA)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unable to tolerate allopurinol 200 mg every day&#xD;
&#xD;
          2. Prior randomization in a clinical study with BCX4208&#xD;
&#xD;
          3. Unstable cardiac disease such as: unstable angina, symptomatic arrhythmia, signs or&#xD;
             symptoms compatible with NYHA Class III or Class IV functional status for congestive&#xD;
             heart failure or angina, history of long QT syndrome, or QTc interval &lt; 350 msec or &gt;&#xD;
             475 msec&#xD;
&#xD;
          4. Poorly controlled hypertension&#xD;
&#xD;
          5. History of severe renal insufficiency&#xD;
&#xD;
          6. Alanine aminotransferase or aspartate aminotransferase values &gt; 2.0 x upper limit of&#xD;
             normal&#xD;
&#xD;
          7. CD4+ cell counts by flow cytometry &lt; 500 cells/mm3&#xD;
&#xD;
          8. Hemoglobin &lt; 10 g/dL or &gt; 18 g/dL (males) or &lt; 10 g/dL or &gt; 17 g/dL (females)&#xD;
&#xD;
          9. White blood cell count &lt; 3.7 x 109/L or &gt; 11 x 109/L&#xD;
&#xD;
         10. Female subjects who are pregnant, breastfeeding, or planning a pregnancy within the&#xD;
             next 4 months&#xD;
&#xD;
         11. Positive serology for hepatitis B surface antigen or hepatitis C antibody or HIV type&#xD;
             1&#xD;
&#xD;
         12. Immunocompromised due to illness or organ transplant&#xD;
&#xD;
         13. Use of systemic immunosuppressive medications or disease-modifying antirheumatic drugs&#xD;
&#xD;
         14. Use of azathioprine or 6-mercatopurine within 14 days of first dose of allopurinol&#xD;
&#xD;
         15. Use of hydrochlorothiazide in doses &gt; 50 mg per day&#xD;
&#xD;
         16. Planned use of herbal or dietary supplements&#xD;
&#xD;
         17. Recipient of any live or attenuated vaccine within 6 weeks of Screening&#xD;
&#xD;
         18. Planned use of uric acid-lowering drugs other than allopurinol&#xD;
&#xD;
         19. Use of systemic corticosteroids within 4 weeks prior to Day 1&#xD;
&#xD;
         20. Use of any investigational drug within 30 days prior to signing the ICF&#xD;
&#xD;
         21. History of clinically significant and relevant drug allergies&#xD;
&#xD;
         22. History of chronic or recurrent infections&#xD;
&#xD;
         23. History of any type of cancer not successfully treated or in full remission for 12&#xD;
             months prior to Screening&#xD;
&#xD;
         24. History of alcohol or drug abuse within the year prior to the signing of the ICF, or&#xD;
             current evidence of substance dependence or abuse&#xD;
&#xD;
         25. Use of other prohibited medications within the timeframes specified in the protocol&#xD;
&#xD;
         26. Other medical conditions which, in the opinion of the Principal Investigator, would&#xD;
             jeopardize the safety of the study subject&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Hollister, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>BioCryst Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oldsmar</city>
        <state>Florida</state>
        <zip>34677</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37923</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <zip>22304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>August 1, 2011</study_first_submitted>
  <study_first_submitted_qc>August 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2011</study_first_posted>
  <disposition_first_submitted>October 4, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>October 4, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 28, 2013</disposition_first_posted>
  <last_update_submitted>October 28, 2013</last_update_submitted>
  <last_update_submitted_qc>October 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gout</keyword>
  <keyword>Hyperuricemia</keyword>
  <keyword>Arthritis</keyword>
  <keyword>Joint Disease</keyword>
  <keyword>Allopurinol</keyword>
  <keyword>Renal Insufficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Gout</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

